Highlights From EULAR 2008, The Annual European Congress Of Rheumatology Half of patients with early rheumatoid arthritis treated with the anti-tumour necrosis factor inhibitor (anti-TNF) infliximab plus methotrexate achieve remission, and up to one in five achieve drug-free remission, according to five-year follow-up results from the BeSt study. Patients treated initially with a combination of infliximab plus methotrexate achieved significantly better functional ability than those given other treatment regimens.
Source: www.medicalnewstoday.comSCOLR Pharma, Inc. Advances Extended-Release Ibuprofen With Initiation Of Clinical Study SCOLR Pharma, Inc. (AMEX: DDD) announced the initiation of the third of three pivotal trials to evaluate the safety and efficacy of its formulation of 12-hour extended-release (ER) ibuprofen for the over-the-counter (OTC) market. The Company expects to complete the trial in late 2008. If approved, the Company believes its ibuprofen product would be the first and only OTC 12-hour, extended-release ibuprofen product on the market in the United States.
Source: www.medicalnewstoday.comCanadian Scientists Report On Pain Research At NIDCR's 60th Anniversary Symposium Nearly everyone has experienced the acute, short-lived pain that occurs after a mild injury, but recent surveys reveal that more than 20% of the population has a chronic pain condition (i.e., pain that has lasted for 3 months or more) and for which treatment is often not very effective (e.g., low back pain, fibromyalgia, migraine headaches). Acute and chronic pain conditions have huge socio-economic costs.
Source: www.medicalnewstoday.comCPPC Calls For A National Framework In England To Help Millions Suffering From Long Term Chronic Pain The Chronic Pain Policy Coalition (CPPC), established to promote better treatment for the 7.8 million who suffer from long-term chronic pain such as severe back pain or depression, is calling for a national chronic pain treatment framework for England in the light of the Darzi review into the future of the NHS.
Source: www.medicalnewstoday.com
# posted by Network @ 1:00 PM
